View Older Stories View More Recent Stories

May 15, 2019 05:00PM Kite to Present New Data From Leading Cell Therapy Portfolio at ASCO 2019
May 9, 2019 05:11PM Gilead Sciences to Provide Free Truvada for PrEP® to Support U.S. Initiative to End the HIV Epidemic
May 6, 2019 04:01PM Gilead Sciences to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14
May 2, 2019 04:02PM Gilead Sciences Announces Second Quarter 2019 Dividend
Apr 30, 2019 04:27PM Gilead Sciences (GILD) CFO Robin Washington to Step Down in Early 2020
Apr 30, 2019 04:27PM Gilead Sciences’ Chief Financial Officer Robin Washington to Step Down in Early 2020
Apr 25, 2019 08:01AM Gilead Sciences (GILD) Reports Topline Data from Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)
Apr 25, 2019 08:00AM Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)
Apr 24, 2019 08:30AM Kite Announces Plans for New State-of-the-Art Facility to Expand Cell Therapy Production Capabilities
Apr 18, 2019 04:05PM Gilead Sciences to Release First Quarter 2019 Financial Results on Thursday, May 2, 2019
Apr 16, 2019 07:01AM Gilead Sciences (GILD), insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for NASH
Apr 16, 2019 07:00AM Gilead and insitro Announce Strategic Collaboration to Discover and Develop Novel Therapies for Nonalcoholic Steatohepatitis
Apr 12, 2019 06:31AM Gilead Sciences (GILD), Novo Nordisk (NVO) Announce Intent to Initiate a Clinical Collaboration in NASH
Apr 12, 2019 04:00AM Gilead Sciences and Novo Nordisk Announce Intent to Initiate a Clinical Collaboration in NASH
Apr 11, 2019 09:18AM Gilead Presents New Data on Viral Hepatitis at the International Liver Congress™ 2019
Apr 11, 2019 02:00AM Gilead Presents New Data in Nonalcoholic Steatohepatitis (NASH) at the International Liver Congress™ 2019
Apr 9, 2019 12:00PM Gilead Announces New Grant Programs Supporting Investigator-Sponsored Research in Liver Diseases
Apr 5, 2019 08:31AM Gilead Sciences (GILD) Submits sNDA to FDA for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
Apr 5, 2019 08:30AM Gilead Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Once-Daily Descovy® for HIV Pre-Exposure Prophylaxis
Mar 28, 2019 05:00AM Gilead Launches HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia
Mar 27, 2019 06:06AM Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019
Mar 26, 2019 08:32AM Gilead (GILD) Announces Japan's MHLW Approved its Biktarvy for Treatment of HIV-1 Infection
Mar 26, 2019 08:30AM Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection
Mar 13, 2019 08:34AM Agenus (AGEN) Secures $7.5M Milestone Payment from Gilead Sciences, Inc. (GILD)
Mar 7, 2019 05:31PM Gilead Sciences (GILD) Announces Data From Two Studies Supporting Further Development of GS-6207
Mar 7, 2019 05:30PM Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies
Mar 6, 2019 05:31PM Gilead (GILD) Presents Data on Biktarvy in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance
Mar 6, 2019 05:30PM Gilead Presents New Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) and TAF-Based Regimens for the Treatment of HIV-1 in Children, Older Adults and Women
Mar 6, 2019 05:30PM Gilead Presents Data on Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) in Virologically Suppressed Adults, Including Those With Pre-Existing NRTI Resistance
Mar 6, 2019 02:13PM Gilead Sciences (GILD) DISCOVER HIV Trial Meets Primary and Secondary Endpoints
Mar 6, 2019 02:10PM Gilead Announces Data Demonstrating Non-Inferiority of Once-Daily Descovy® vs. Once-Daily Truvada® for Prevention of HIV Infection
Mar 5, 2019 04:31PM Gilead Sciences (GILD) EVP of Oncology Therapeutics, Alessandro Riva, to Leave
Mar 5, 2019 04:30PM Gilead Announces Senior Management Change
Mar 5, 2019 04:05PM Gilead Sciences to Present at the Barclays Global Healthcare Conference on Tuesday, March 12
Feb 11, 2019 04:32PM Gilead Sciences (GILD) Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to NASH Doesn't Meet Primary Endpoint
Feb 11, 2019 04:30PM Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
Feb 4, 2019 04:02PM Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend
Jan 24, 2019 08:30AM Agenus Closes $150 Million Immuno-Oncology Transaction with Gilead
Jan 22, 2019 04:05PM Gilead Sciences to Release Fourth Quarter and Full Year 2018 Financial Results on Monday, February 4, 2019
Jan 8, 2019 01:00AM Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir)
Jan 6, 2019 05:30PM Gilead Sciences and Yuhan Corporation Announce Collaboration and License Agreement to Develop Novel Investigational Treatments for Advanced Fibrosis Due to Nonalcoholic Steatohepatitis
Jan 2, 2019 09:01AM Gilead Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7
Dec 20, 2018 08:28AM Agenus (AGEN), Gilead Sciences, Inc. (GILD) Announces Collaboration to Develop Immuno-Oncology Therapies
Dec 20, 2018 07:30AM Gilead and Agenus Enter Into Collaboration to Develop Immuno-Oncology Therapies
Dec 20, 2018 07:30AM Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies
Dec 19, 2018 08:02AM Gilead Sciences (GILD), Scholar Rock (SRRK) Announce Pact to Develop Novel Therapies for Fibrotic Diseases
Dec 19, 2018 08:01AM Gilead Sciences and Scholar Rock Announce Strategic Collaboration to Develop Novel Therapies for Fibrotic Diseases
Dec 10, 2018 05:51AM Gilead Sciences (GILD) Announces Daniel O’Day as Board Chairman & CEO
Dec 10, 2018 01:00AM Gilead Sciences Names Daniel O’Day Chairman and Chief Executive Officer
Dec 4, 2018 08:33AM Gilead Sciences (GILD) Announces China's NMPA Approves Harvoni for Treatment of Chronic HCV Genotype 1-6
View More Recent Stories View Older Stories